MCL1 and diffuse large B-cell lymphoma: Apart from BCL2, BCL‐XL and MCL1 may also represent promising therapeutic targets with a subset of DLBCL cells displaying high sensitivity to BH3‐mimetics selectively targeting BCL‐XL (e.g. A1331852) or MCL1 (e.g. S63845).13